The Importance of Periostin in Periodontal Health and Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01180920

Enrollment

Registered

2010-08-12

Start date

2011-06-30

Completion date

2013-02-28

Last updated

2014-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-diseased Patients, Periodontal Disease

Keywords

Dental, Periodontal, Surgery, Gums

Brief summary

The goal of this study is to determine the clinical importance of Periostin in oral health and disease. The long-term goal will be to develop practical applications for the diagnosis, treatment, prevention and cure of human periodontal diseases.

Detailed description

It is hypothesized that Periostin levels are decreased during periodontal diseases, thereby, elevating the hosts' susceptibility to periodontal breakdown. The specific aims are the following; To determine if Periostin is a biomarker of periodontal disease, and To evaluate Periostin in periodontal tissue healing and homeostasis by harvesting healthy or diseased tissue from 22 patients requiring periodontal surgery.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Inclusion criteria for diseased subjects: * Diagnosis of generalized chronic or aggressive periodontitis * At least four periodontal sites with probing depth (PD) ≥6 mm, evidence of clinical attachment loss (CAL), and bleeding on probing (BOP). Inclusion criteria for healthy individuals will include PD \<4 mm, no evidence of attachment loss, and \<10% of sites with BOP * Need an open flap procedure Inclusion criteria for non-diseased subjects: * Subjects requiring a gingivectomy or crown lengthening procedure

Exclusion criteria

* History of alcoholism or drug abuse * Medical conditions that may affect the outcome such as autoimmune diseases, diabetes, immunocompromised subjects, neurologic or psychiatric disorders, systemic infections, etc. * Chronic medications known to affect the periodontal status (calcium antagonists, anticonvulsives, immunosuppressives, anti-inflammatory medications, Depo-Provera contraceptive injection users, new oral contraceptives users within 3 months of baseline or subjects that are planning on, starting oral contraceptives during the study. * Antibiotic therapy within 3 months of the baseline visit, and/or antibiotic therapy needed for infective endocarditis prophylaxis. * Current use or quit smoking less than one year ago with a pack-year history of more than or equal to 10. * Untreated cavities

Design outcomes

Primary

Measure	Time frame	Description
To determine whether the expression of Periostin within the periodontal tissues is affected in periodontal disease progression in-vivo and whether Periostin levels are associated with disease susceptibility.	Baseline	Periostin levels from gingival crevicular fluid (GCF), saliva, serum and tissue will be analyzed in both health and disease. Total RNA and protein extracts will be isolated and utilized for relative quantitative measurements.

Secondary

Measure	Time frame	Description
explore the expression dynamics of Periostin during periodontal healing in healthy and diseased periodontia.	8wks	A longitudinal study will also be performed to evaluate Periostin levels in GCF/wound fluids and saliva over time during periodontal tissue healing and homeostasis.

Countries

United States

Outcome results